Podcasts about Janssen

In this episode, we discuss the problem of miscitation. How often are citations to the scientific literature outright misleading? Do we really need to spell out that people  are supposed to read what they cite? What can we learn from other fields? Or should we just live with the fact that a decent percentage of citations in the literature are wrong? Enjoy.    Careless citations don't just spread scientific myths – they can make them stronger (Nature) Cobb, C. L., Crumly, B., Montero-Zamora, P., Schwartz, S. J., & Martínez Jr, C. R. (2024). The problem of miscitation in psychological science: Righting the ship. American Psychologist, 79(2), 299–311. Simmering, M. J., Fuller, C. M., Leonard, S. R., & Simmering, V. R. (2025). Cognitive biases and research miscitations. Applied Psychology, 74(1), e12589. Qinyue Liu, Amira Barhoumi, Cyril Labbé. (2024). Miscitations in scientific papers: Dataset and detection. International Workshop on Bibliometric-enhanced Information Retrieval. Glasgow, United Kingdom. Lazonder, A. W., & Janssen, N. (2022). Quotation accuracy in educational research articles. Educational Research Review, 35(1), https://doi.org/10.1016/j.edurev.2021.100430 James, W. (1914). The energies of men. New York : Moffat, Yard and Company. http://archive.org/details/energiesofmen00jameuoft Beyerstein, B.L. (1999) Whence cometh the myth that we only use ten percent of our brains? In, S. Della Sala (Ed.), Mind Myths: Exploring Everyday Mysteries Jergas, H., & Baethge, C. (2015). Quotation accuracy in medical journal articles—A systematic review and meta-analysis. PeerJ, 3, e1364. https://doi.org/10.7717/peerj.1364 Bruton, S. V., Macchione, A. L., Brown, M., & Hosseini, M. (2025). Citation Ethics: An Exploratory Survey of Norms and Behaviors. Journal of Academic Ethics, 23(2), 329–346. https://doi.org/10.1007/s10805-024-09539-2 Simkin, M., & Roychowdhury, V. (2006). Do You Sincerely Want to Be Cited? Or: Read Before You Cite. Significance, 3(4), 179–181. https://doi.org/10.1111/j.1740-9713.2006.00202.x Simmering, M. J., Fuller, C. M., Leonard, S. R., & Simmering, V. R. (2025). Cognitive biases and research miscitations. Applied Psychology, 74(1), e12589. https://doi.org/10.1111/apps.12589 Bluebook: https://www.legalbluebook.com  

In this conversation, Paul Blankley and Ryan Janssen, founders of Zenlytic, drop in to discuss the massive shift in how we build software and handle data. We trace their journey from studying early NLP and Transformers at Harvard right when the BERT paper dropped, to building a company that relies on cutting-edge LLMs. As far as I know, they're the first to use LLM's for analytics.We dive deep into the reality of the agentic era: engineers are no longer writing the bulk of the code; they are managing agents, verifying outputs, and maintaining ridiculously high standards. We also explore why the industry needs to embrace "net negative scaffolding" as models get smarter, and why having good "taste" might be the ultimate human moat left in tech.Bonus: To prove that software development is changing faster than ever, we literally "vibe coded" a brand-new CRM called "Slop Force" in 20 minutes during this episode. Zenlytic: https://www.zenlytic.com/

To whom will we preach the Gospel, and with whom will we do it with together?

Recorded Live at One Heart Church (Port Lincoln) at the 9am Service, on the 8th of March 2026.

Juan woont in een oud huis. De CV ketel loopt leeg. Maar waar zit de lekkage? Een alledaagse zorg die het leven toch wel even op slot kan zetten. Marc leeft mee en kan zich - empatisch begaafd als hij is - maximaal inleven. Marc (Juan) nam een Guinness Blonde IPA mee. In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

Ben Ennis and Brent Gunning wrap up Thursday by chatting with Anthony Petrielli from Leafs Notebook. They discuss whether the Leafs need to make more moves before the deadline, what additions could help them compete next season, and their goaltending situation. Anthony also addresses Auston Matthews' performance and the coaching staff's deployment decisions. After the break, former NHLer Cam Janssen (25:12) joins to talk about Colton Parayko's potential trade to Buffalo, the impact of using a no-move clause, and the possibility of Jordan Binnington being moved as well. They also discuss a possible front-office shakeup in St. Louis and Alex Steen's first year in charge. Ben and Brent conclude by speculating on Doug Armstrong's future if not with the Blues. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliate.

Who will we share Jesus with this week?

While Jesus is in the garden with his disciples, Judas comes with high priests and soldiers to arrest Jesus. “Put your sword back into its place; for all who take the sword will perish by the sword. Do you think that I cannot appeal to my Father, and he will at once send me more than twelve legions of angels? But how then would the scriptures be fulfilled, which say it must happen this way?” Find out all that is happening on both our campuses during the sacred season of Lent—beginning with Ash Wednesday on Feb. 18 and leading up to Easter Sunday on April 5. Visit villagepres.org/lent.Sunday service times are 9 a.m., 11 a.m., and 4 p.m. at the Mission Campus in Prairie Village, Kansas, and 10 a.m. at the Antioch Campus in Overland Park, Kansas. If you are unable to attend in person, you can worship online at villagepres.org/online or here on YouTube. Support the showContact Village Presbyterian Churchvillagepres.orgcommunications@villagepres.org913-262-4200Have a prayer request? pastoral-care@villagepres.orgFacebook @villagepresInstagram @villagepreschurchYouTube @villagepresbyterianchurchTo join in the mission and ministry of Village Church, go to villagepres.org/giving

This week, Joanne welcomes master gardener Ingrid Janssen to the podcast to discuss the inspiring work being done by Little Forests Durham, a nonprofit organization focused on planting Miyawaki mini forests throughout Durham Region. About Little Forests Durham Little Forests Durham is a volunteer-run community non-profit organization based in Durham Region, Ontario, Canada, focused on giving tools, knowledge, and support to people, communities, organizations and local authorities to plant Little Forests in their neighbourhoods and communities. Topics Covered Ingrid's background as a Durham Master Gardener, seed collector, and advocate for native trees How Little Forests Durham was founded in 2024 and inspired by Little Forests Kingston What a Miyawaki mini forest is and how the method aims to compress forest succession into 20-30 years Why these forests are planted using dense layers of native trees and shrubs to mimic a natural forest community The importance of soil preparation, including cardboard, compost, and mulch to suppress weeds and build fungal-rich soil How sites are chosen through collaboration with municipal staff, parks departments, and local partners Why publicly accessible land is a priority for Little Forests Durham projects The logistics behind site prep, including access for trucks, compost delivery, mulch spreading, and volunteer coordination How volunteers help with planting days, often in large numbers, making it possible to plant hundreds of trees and shrubs in a short time Why planting design still matters, even in a more naturalized system, with careful placement of canopy trees, understory trees, and shrubs The realities of maintenance, including weeding, invasive species removal, tree protection, fencing, and monitoring for drought How mini forests help address climate change by increasing biodiversity, cooling urban spaces, and creating habitat for wildlife The role of partnerships with organizations such as Rotary Clubs, conservation authorities, Green Communities Canada, Greenbelt Foundation, and Trees for Life The group's ambitious goal of planting 30 mini forests by 2030 in Durham Region How listeners can support the effort through volunteering, joining the team, donating, or helping bring projects to their own communities The idea that homeowners can create smaller-scale versions in their own yards, known as pocket forests Ingrid's love of native trees, with a special mention of her flowering dogwood, grown from seed she collected herself Takeaways and Tips Mini forests do not require huge spaces. Even a small corner of a park or a backyard can support a meaningful planting. Native trees and shrubs matter. They support biodiversity, wildlife, and long-term ecological health. The Miyawaki method is about community. It brings together people, plants, fungi, wildlife, and local organizations in one shared effort. Good site access is essential. Successful projects need room for compost, mulch, tools, and tree delivery. Volunteer-friendly planning makes all the difference. Clear layouts and simple planting instructions help create a positive experience. Soil prep is key. Cardboard, compost, and mulch help suppress weeds and create better conditions for young trees to thrive. Maintenance matters. The first few years require protection from rabbits, trampling, invasive weeds, and possible drought. Climate action can be local. You don't have to wait for large systems to change. Communities can begin by planting trees where they live. Small efforts add up. Whether it is joining a planting day, donating materials, or creating a pocket forest at home, every action helps. You can find Little Forests Durham online at www.littleforestsdurham.ca and on Instagram, and Facebook. Have a topic you'd like Joanne to discuss? Email your questions and comments to downthegardenpathpodcast@hotmail.com, or connect with Joanne on her website: down2earth.ca Find Down the Garden Path on Instagram, Facebook, and YouTube: @downthegardenpathpodcast. Down the Garden Path Podcast On Down The Garden Path, professional landscape designer Joanne Shaw discusses down-to-earth tips and advice for your plants, gardens and landscapes. As the owner of Down2Earth Landscape Design, Joanne Shaw has been designing beautiful gardens for homeowners east of Toronto for over a decade. She does her best to bring you interesting, relevant and useful topics to help you keep your garden as low-maintenance as possible.  In Down the Garden Path: A Step-By-Step Guide to Your Ontario Garden, Joanne and fellow landscape designer Matthew Dressing distill their horticultural and design expertise and their combined experiences in helping others create and maintain thriving gardens into one easy-to-read monthly reference guide. Get your copy today on Amazon. Don't forget to check out Down the Garden Path on your favourite podcast app and subscribe! You can now catch the podcast on YouTube.

(Insight Meditation Community of Richmond) In this talk, we explore how our stress, emotions, and habits don't arise randomly but depend on specific conditions. By learning to recognize and understand these conditions in meditation and daily life, we begin to loosen reactivity and cultivate the causes for greater freedom and peace.

(Insight Meditation Community of Richmond) In this talk, we explore how our stress, emotions, and habits don't arise randomly but depend on specific conditions. By learning to recognize and understand these conditions in meditation and daily life, we begin to loosen reactivity and cultivate the causes for greater freedom and peace.

Soms test het leven je. Bij Marc is dat nu het geval. Sanne is geblesseerd. Het huishouden rust op z'n schouders. Z'n werkgever vraagt veel van hem. De winter duurt hem te lang. Oh en dan is er nog een goed voornemen waar hij aan vast probeert te houden, namelijk niet meer koken uit zakjes. 'Niet te doen!', aldus Marc die met z'n handschoentjes aan staat te kneuzen in de keuken.Juan (Marc) nam een Erdinger Schneeweisse mee. Geen idee wat dat is. In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different subtypes. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we're going to explore the evolving landscape of treatment strategies in head and neck cancer management, including locoregionally advanced head and neck squamous cell carcinoma, which happens to be on the rise in United States, in part due to spike in HPV-mediated oropharyngeal cancers. We're also going to discuss the emerging strategies of using blood-based biomarkers to really advance personalized therapy. Joining me for this discussion is Dr. Ari Rosenberg. He's a medical oncologist focused on head and neck cancer, and he's an associate professor – congratulations on the recent promotion – at the University of Chicago. The University of Chicago has really produced luminaries in this field, Dr. Rosenberg included. I've had the pleasure of getting to know Dr. Ezra Cohen over the years, who really had his grounding there, and of course Everett Vokes, former ASCO President. I'm really looking forward to this conversation, Ari. Thanks so much for joining us. Dr. Ari Rosenberg: Thanks, Monty. Thanks for the invitation. Dr. Monty Pal: You got it. And just a quick note for our listeners, our full disclosures are going to be in the transcript at the end of this episode. So let's start with the basics, if you don't mind. So, head and neck cancers are very diverse and they're challenging, right? In the sense that they're near vital organs, the treatments, you know, as we all saw during fellowship, if not now in clinical practice. They can really have such a major impact on vital organ function, speech, swallowing, et cetera. Can you just comment on head and neck cancers that are on the rise in the U.S.? I alluded to this briefly. Particularly, we've heard this in the context of colorectal cancer and so forth. Are you actually seeing younger adults being affected by this? Dr. Ari Rosenberg: Yeah, thanks for that. The vast majority of head and neck cancers are head and neck squamous cell carcinomas, as I'm sure many of the listeners recall as well from fellowship or their current training. And as you alluded to, the organ function, long-term and functional quality of life outcomes are quite important, particularly in the context that these develop in high value real estate, parts of our head and neck area that we use for speaking, swallowing, all sorts of other essential functions as well. As you also alluded to, we think of this in two different particular subtypes of head and neck cancer. The historical head and neck cancer from 50, 60 years ago was almost exclusively related to carcinogen exposure, tobacco, alcohol use, and that subtype of carcinogen-induced head and neck cancer has been slowly declining. However, over the last now several decades, we've been seeing an increase in primary oropharyngeal squamous cell carcinoma, mostly tonsil, base of tongue. These are attributable to HPV, human papillomavirus exposure. And that's now the majority of the head and neck cancers that we tend to see in our clinic. As you also alluded to, these have very different prognoses as well. HPV-related head and neck cancer has a much more favorable prognosis where much of the interest has been in can we de-intensify to optimize long-term function? But then the non-HPV-related head and neck cancer, or what we call HPV-negative head and neck cancer, continue to be very, very challenging. We only managed to cure about half of these folks, with many of these patients developing the current disease. These patients, in addition to being difficult to treat, also have major impacts both in terms of the treatments they undergo as well as their disease that can impact their function and quality of life. And you hinted at this a little bit, but we have been seeing an increase in younger patients with HPV-negative head and neck cancer as well, which is quite concerning. Younger patients, oftentimes never smokers, never drinkers, who are developing non-HPV-negative head and neck cancer. And that's been a little bit of a more recent trend that we've been seeing as well. So, definitely a lot of work to be done to optimize and improve outcomes across all of these different head and neck cancer subtypes. Dr. Monty Pal: I mean, I'm just curious, you know, in the context of colorectal cancer, one of the things that we talk about is the potential role of the microbiome driving some of these young-onset cancers with, you know, perhaps there being an impact on, for instance, inflammation and the gut and what have you. Tell me about head and neck cancer. Is this anything known as to why younger patients might be getting diagnosed with non-HPV type cancers? It's odd to me. Dr. Ari Rosenberg: Yeah, it's a great question. A lot of people are working on it. I think we folks have hypotheses, but it hasn't totally panned out exactly what's going on there. It does have a little bit more of a tendency towards women, whereas historically head and neck cancer is much more common in men than it is in women. But lots of people working on that, whether it's related to chronic inflammation, whether it's related to the microbiome. Whether it's related to dental exposure, dental work. So, a lot of folks trying to parse that out because I agree with you, it needs to be identified alongside improving treatment paradigms for these patients, the young ones and the older patients as well. Dr. Monty Pal: Interesting, interesting. You know, one of the phenomena that was sort of coming around when I was in training 25 years ago was this role of sort of induction therapy for head and neck cancers. And of course, it's really come full circle now to include checkpoint inhibitors and so forth. Tell me a little bit about this and how you apply it, maybe in an HPV-mediated context, maybe in a non-HPV context. Dr. Ari Rosenberg: Yeah, absolutely. Induction chemotherapy, as you alluded to, or neoadjuvant chemotherapy, depending on what the locoregional treatment approach is. Similar to other cancer types where systemic control early on has many potential advantages in this setting. Now, in head and neck cancer, even though induction chemotherapy is quite active in head and neck cancer, both HPV-positive and HPV-negative with pretty good response rates. A survival advantage for all comers with local regionally advanced disease remains unproven. There's been two randomized trials, both underpowered, but essentially did not show a survival advantage, showing that induction chemotherapy for all patients with locoregionally advanced and neck cancer can't be justified for a survival advantage. That being said though, there remains a number of potential advantages of giving induction or neoadjuvant chemotherapy, of course, improving systemic control and debulking the disease early on has potential advantages, and predicting the responsiveness to subsequent radiation treatment. We know for some time in head and neck cancer that the percentage of shrinkage or the response to induction chemotherapy actually predicts outcome related to radiation as a dynamic biomarker where response can be used to select patients, for example, for de-escalated radiation has been an area of active investigation, active research. And it also remains a key opportunity to evaluate predictive biomarkers and understanding pre and post treatment to better understand the biology. I'll just add to your question that recently over this past year, we also saw phase 3 data for neoadjuvant immunotherapy for a subset of head and neck cancer that is surgically resectable. And so that's reintroducing the potential benefit in the immunotherapy era of incorporating immunotherapy in the neoadjuvant or the induction setting as part of the evolving treatment paradigm for these diseases. Dr. Monty Pal: That's really interesting. And you kind of alluded to already several topics that I plan to hit on, you know, for instance, the role of immune checkpoint inhibitors, induction, chemotherapy, and so forth. And you started to touch on biomarkers. And of course, I think that's something near and dear to many of us in academic oncology. One thing that we've started talking a lot about in the context of colorectal cancer is circulating tumor DNA. How do you think this might fit in the context of head and neck cancer? Can you give us a flavor for that? Dr. Ari Rosenberg: Yeah, absolutely. In head and neck cancer, the current landscape is most developed for circulating tumor DNA for HPV-related head and neck cancer. The advantage of HPV-related head neck cancer is that you have a distinctive HPV DNA that does tend to spill out into the peripheral blood and can be detected using various different blood-based assays. And because of that advantage as a tissue agnostic approach, it turns out that a number of HPV DNA plasma assays are actually quite sensitive and quite specific. And a number of them have indeed been commercialized. Of course, not only for detecting a baseline, but also grading responsiveness during treatment and probably most importantly in the post-treatment surveillance setting, the detection of HPV DNA in the plasma remains a very important and substantial predictor of developing recurrent disease. There's been a number of trials that have been emerging looking at ctDNA and HPV-related head and neck cancer, using it, for example, as a strategy to deescalate patients. That was something we saw this past ASCO from the Dana-Farber group, and also using it to early detect recurrence and potentially intervene earlier for patients with minimal residual disease positivity. So, that remains evolving and as many folks are, I think, already using it in the clinic. But ctDNA also has a lot of potential for HPV-negative head and neck cancer. This is actually a bit more challenging to develop because you don't have that HPV DNA that you can track predictably because the tumor is an HPV- negative disease are much more heterogeneous, but there are a number of data that are coming out both for personalized assays such as Signatera or some of the other assays that require tumor. Unlike colon cancer, which you referenced, where most patients get surgery upfront, in head and neck cancer, many of the patients receive non-surgical pre-chemoradiation. So sometimes the amount of tumor available to generate a personalized assay is more limited and can be one of the challenges that we see in head neck cancer. But certainly that also seems to be emerging. And there's also further assays that are being developed for HPV-negative head neck cancers, such as methylomic signatures and others that may be tissue informed or tissue agnostic. And these are also emerging, particularly in the post-treatment surveillance setting as strong predictors of recurrent disease. So while we're certainly behind some of these other more common tumor types, colon cancer, lung cancer, we're right there with them and more and more trials are going report out, including a number of trials in our upcoming [University of Chicago] Head and Neck Cancer Symposium where I'll be presenting some data and others in the field will be presenting some data looking at ctDNA both for HPV-positive and for HPV- negative to try to improve outcomes for these patients. Dr. Monty Pal: That's so interesting. I've got to tell you that in kidney cancer, what I deal with day to day is a very low shedding disease, right? So techniques as opposed to ctDNA looking for tumor-informed information, that might be less preferred to something like methylomics where you might not necessarily be so contingent on what's happening in the primary tumor. I'm really interested in you mentioning that. Just a point of clarification, this is something I'm trying to wrap my head around. You'd mentioned circulating tumor HPV DNA, right? I assume this is markedly different from just looking for HPV titers in the patient, right? So is this actually incorporated elements of HPV within, you know, essentially host genome, if you will? Dr. Ari Rosenberg: Yeah, correct. This is circulating tumor HPV DNA. And we think of it biologically as a plasma-based tumor DNA biomarker that's specific for HPV-related head and neck cancers. Dr. Monty Pal: Got it, got it. It makes me wonder whether or not this might be applicable to diseases like cervical cancer and so forth where there's also extensively, you know, biology driven by HPV. Is that fair? Dr. Ari Rosenberg: Yes, definitely. And in the head and neck cancer field, much of this ctDNA actually was derived from a different viral mediated head neck cancer, is less common in the U.S., but nasopharyngeal cancer, which is oftentimes associated with EBV. That has been a biomarker for quite some time in nasopharyngeal cancer. Of course, in places where EBV-associated nasopharyngeal cancer, is endemic, such as East Asia, this has been around for quite some time, but we've been using that in the U.S., and there's been trials that have used EBV DNA plasma to predict recurrence and stratify for adjuvant treatment, for example. And so now with HPV, it's much more applicable to our US population because the vast majority of our head and neck cancer patients that we see in the US that are viral mediated in the US tend to be HPV-related. So having assays that we can use to improve outcomes for that biological subset remains of particular interest for us. Dr. Monty Pal: Yeah, that's fascinating. By the way, for the fellows listening, there's tons of boards pearls here that Dr. Rosenberg shared, EBV-associated cancers, the role of HPV and treatment association. So if you're recertifying anytime soon, I definitely think there's notes to take from this conversation indeed. I wanted to shift gears a little bit. And obviously, you're a prolific researcher. I don't think anyone goes through their fellowship in medical oncology without recounting these experiences of our head and neck patients really suffering from treatment-related toxicities. It's a real challenge. And I'm just wondering, I know a big body of work that you're focused on is really using multimodality treatment paradigms to perhaps reduce the cumulative treatment burden of patients with head and neck cancers. Can you talk about that a little bit? Dr. Ari Rosenberg: Yeah, definitely. Thanks for the question. And before I start going into some of the strategies, I'll just say that head and neck cancer, this is particularly for the fellows that are listening as well, just in reference to your prior comment, that this is really a multidisciplinary disease. At our center, all head and neck cancer patients are seen upfront at that first visit by all three specialties, med onc, rad onc, and surgery, because the choice and sequencing of modalities to optimize not only survival, but also functional quality of life outcome is so critical. And I think that's probably the biggest takeaway for anyone who treats a lot of head and neck cancer or will be treating a lot of head and neck cancer in the clinic. But in terms of more specific attempts at trying to optimize some of those parameters that you described, we really think about these separately in terms of HPV-positive and HPV-negative head and neck cancer. For HPV-positive head and neck cancer, the cure rates are quite high with chemo radiation, although not for everyone. There's still about 15, 10 to 15 % of folks that will develop a recurrence. But for the vast majority of patients, standard chemoradiation is quite a cure to therapy, but the toxicity associated with that can be quite substantial. And so there's been a number of attempts to try to deescalate treatment. It turns out that deescalating everyone with locoregionally advanced HPV-positive head and neck cancer is not a good strategy because it's not able to select out the patients that really do need full dose treatment. And we have seen some negative trials that show inferior outcomes when everyone is deescalated. But what does remain promising is again, trying to select out who the best candidates are for deescalated treatment. The folks at MSK have hypoxia imaging that they're using in trials that looks quite promising to select for the more favorable deescalatable biology. At our center, we've been interested in using induction chemotherapy to stratify response and select patients for deescalated treatment with excellent survival outcomes and reduce toxicity with deescalated treatment. And more recently, ctDNA that us and other groups, such as the Dana-Farber group, is using. And that also looks quite promising. Again, how do you select the patient who will do well with less radiation versus the ones that really need the full doses and volumes of radiation? And then for HPV-negative head and neck cancer, this is a much trickier disease because already the survival outcomes are not like we want it to be. Trying to figure out how to improve survival outcomes remains an important thing. Using immunotherapy seems to be one of the key cornerstones to that. But these are patients that also suffer from a lot of toxicity related to their treatment. We completed a trial not too long ago that we published this past year where we, in HPV-negative head and neck cancer patients, de-intensified the radiation for responders to neoadjuvant chemoimmunotherapy. And those patients did similar, if not even a little bit better, than the non-responders who got full dose treatment. So something that does warrant further investigation as well. How do we not only improve survival for those patients, but also reduce some of the long-term toxicities? Dr. Monty Pal: This is brilliant. I'm taking so many notes as you were mentioning these items. There are so many areas where I think the research crosses over. I already mentioned, know, ctDNA, for instance, and metabolomics and the places where that might apply to kidney cancer. The hypoxia imaging really caught my ear too. Obviously, kidney cancer is disease highly predicated on hypoxia. So thank you for all of this. We've got about a minute or so. So, I'm going to ask you for a really tall task here. Can you tell us what you foresee being some of the biggest challenges that sort of lie ahead and head and neck cancer. You've already kind of alluded to it with ongoing research, but if you had to pick maybe 2, 3 problems, the very most that we really need to get to and head and neck cancer, what would that be? Dr. Ari Rosenberg: Yeah, that's a great question. Obviously, lots of things to be done, but if I'm going to limit it to just a couple, I would say number one is really trying to improve the survival for HPV negative local regionally advanced head and neck cancer. We talked early on about how we are seeing, you know, of course we see many of these people that were smokers and drinkers, but also seeing these in younger patients, in patients without a history of tobacco use. Some of these are very biologically aggressive and we need better treatments beyond surgery, beyond chemo radiation, beyond immunotherapy to improve outcomes for these patients and cure more of them. So, I would say that's one big area. And the other is, which we didn't speak about so much in this talk, but remains one of the biggest challenges that we see in the clinic is the recurrent metastatic head and neck cancer patients. This is an incredibly challenging disease to treat, not only with poor survival, but also with substantial impacts on quality of life and function. mean, these are bad recurrences that cause a lot of pain, functional deficits, really impacts quality of life as well. So developing novel therapies, many of which are currently in clinical trials and many of which are currently continuing to be developed, remains so critical. How do we develop better systemic therapies, better targeted therapies, better biomarkers for recurrent metastatic head neck cancer to improve their survival and quality of life and functional outcomes. Those are the two big areas that require the most work at this time within the head and neck cancer field. Dr. Monty Pal: That's brilliant. I mean, I have to tell you I could probably talk to you all day about this, such a fascinating topic. It's a very exciting time in the field. Thank you, Dr. Rosenberg, for all your incredible contributions and thanks for sharing with us your insights on the ASCO Daily News Podcast. Dr. Ari Rosenberg: Yeah, and thanks for the introduction. Hope to do it again soon. Dr. Monty Pal: And many thanks to our listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. More on today's speakers:      Dr. Monty Pal   @montypal  Dr. Ari Rosenberg @AriRosenbergMD Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:       Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical      Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Ari Rosenberg:     Stock and Other Ownership Interests: Privo Technologies Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas Pharma, Regeneron, RAPT Therapeutics, Geovax Labs, Janssen, Summit Therapeutics Speakers' Bureau: Coherus Biosciences Research Funding (Inst.): Hookipa Biotech, EMD Serono, Purple Biotech, Bristol-Myers Squibb/Celgene, BeiGene, Abbvie, Astellas Pharma, Pfizer, Janux Therapeutics

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

The early church grew through devotion, worship, and genuine love for one another. When community is rooted in Christ, the Lord Himself adds to our number day by day.

Learn about Alignable's Business Person of the Year Award from recipient and Toastmaster Janet Janssen.

Let us make Jesus and His will the standard of our lives.

Send a textPodcast 3: Teaching Strategies and Education TipsDNP Website Link: https://amrossi359.wixsite.com/mysitePost-Survey Link: https://ufl.qualtrics.com/jfe/form/SV_3XjGBKEzMxll6HcThis is part three of a three-part podcast series. In this episode, we will discuss teaching strategies and education tips. ReferencesMuijsenberg, A. J., Houben-Wilke, S., Zeng, Y., Spruit, M. A., & Janssen, D. J. (2022). Methods to Assess Adults' Learning Styles and Factors Affecting Learning in Health Education: A Scoping Review. Patient Education and Counseling, 107, 107588. https://doi.org/10.1016/j.pec.2022.107588 Wong, C. I., Desrochers, M. D., Conway, M., Stuver, S. O., Mahan, R. M., & Billett, A. L. (2023). Improving Home Caregiver Independence with Central Line Care for Pediatric Cancer Patients. PEDIATRICS, 151(4). https://doi.org/10.1542/peds.2022-056617 

Breaking bread together is a spiritual activity and a venue for spiritual infilling.

Osteosarcoma Webinar Series: David Ulmert, MD, PhD, an Associate Professor at UCLA, discusses his OutSmarting Osteosarcoma funded work (Because of Sydney) on high-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches.Dr. Ulmert will discuss his lab's work investigating how osteosarcoma responds to LRRC15-targeted radiotherapy, with patient translation anticipated this year. Using high-throughput technologies, the team will identify biomarkers, predictive models, and key transcriptional regulators driving the TGFβ–LRRC15 axis. He will review how radiopathobiological changes and immune reprogramming are being mapped to uncover druggable events and inform co-treatment strategies, accelerating near-term impact on patient studies and next-generation therapeutic development.Dr. David Ulmert is an expert in oncology and biotechnology, specializing in cancer biomarkers and targeted therapies. His research focuses on antigens secreted by luminal tissues as novel cancer-specific targets and circulating biomarkers. He developed high-affinity antibodies against androgen receptor-regulated enzymes hK2 and PSA, now in clinical trials across the US, Europe, and Australia—in collaboration with Janssen—for radioimmunotheranostics, CAR-T therapy, and bispecific targeting. His lab also developed DUNP19, an LRRC15-targeting antibody licensed to Lantheus, with a Phase 1 trial in osteosarcoma planned for 2025. Dr. Ulmert leads UCLA's Preclinical Theranostics Program and conducts population-based studies on cancer biomarkers and risk factors with international collaborators. He is widely recognized for advancing prostate cancer research and translational immunotheranostics.

Theo Janssen, voetbalicoon en huidig trainer van De Treffers, schuift aan bij Alex Pastoor voor een openhartig gesprek over roken, voetbal, leiderschap en de kunst van het trainen. Van zijn tijd bij Vitesse, FC Twente en Ajax tot zijn huidige rol als trainer. Hoe ga je als speler om met discussies tussen trainers en spelers? Waarom is de 'waarom-vraag' zo cruciaal in de ontwikkeling van jonge voetballers? En hoe verras je spelers nog in een tijd waarin alles al voorbereid lijkt? Janssen reflecteert op zijn samenwerking met trainers als Ronald Koeman en Fred Rutten, en vertelt hoe hij als jonge speler omging met alle aandacht. Ook komt de rol van pech en mazzel in een voetbalcarrière ter sprake, en het belang van analyseren - zowel als speler als trainer. Een gesprek vol voetbalinzicht, persoonlijke verhalen en de nodige humor.See omnystudio.com/listener for privacy information.

In the rural reaches of Florida's Panhandle, where longleaf pines line quiet roads and neighbors know each other by the sound of their engines, a sexual battery case in the unincorporated community of Fountain exposed how far the state's legal system will go to punish crimes against children. This episode examines the case and the legal architecture behind it.VICTIM PROFILE: The victim was a minor between the ages of twelve and seventeen living in Bay County, Florida. Her identity is protected under state law. What the record shows is that her willingness to come forward and testify at trial formed the foundation of the prosecution's case. Without her testimony, the legal system would have had nothing to act upon. Her courage carried a weight that no verdict can fully acknowledge.THE CRIME: In 2020, allegations surfaced that Brandon Paul Janssen had committed sexual battery against the victim in Fountain, a small unincorporated community in Bay County. The Bay County Sheriff's Office launched an investigation in coordination with the Gulf Coast Children's Advocacy Center, which provided forensic interview support for the minor. During questioning, Janssen confessed to the acts. Prosecutors charged him with two counts of sexual battery on a minor under Florida Statute 794.011(4)(b), each carrying the potential for life imprisonment.THE INVESTIGATION: The Bay County Sheriff's Office led the case with the Gulf Coast Children's Advocacy Center handling victim support and forensic interviews. Janssen's confession became a focal point at trial, with his defense challenging its admissibility on grounds of voluntariness and Miranda compliance. Prosecutor Jeff Moore presented six witnesses before Bay County Circuit Court Judge Timothy Register. The defense also raised hearsay objections to certain testimony. After roughly one hour of deliberation, the jury returned guilty verdicts on both counts.CURRENT STATUS: On November 13, 2023, Janssen received two consecutive life sentences without the possibility of parole. He was designated a sexual predator under Florida law, ensuring lifetime registration and supervision. He appealed to the First District Court of Appeal, which affirmed the convictions and sentences on August 27, 2025, under docket number 1D2023-3176. As of early 2026, Janssen remains incarcerated at Century Correctional Institution.Support Obscura: https://www.patreon.com/obscuracrimepodcast/Our Sponsors:* Check out BetterHelp: https://www.betterhelp.com* Check out Chime: https://chime.com/OBSCURA* Check out Mood and use my code OBSCURA for a great deal: https://mood.com* Check out Quince: https://quince.com/OBSCURA* Check out TruDiagnostic and use my code OBSCURA20 for a great deal: https://www.trudiagnostic.comSupport this podcast at — https://redcircle.com/obscura-a-true-crime-podcast/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Agile change management in higher education is no longer optional. Institutions are navigating continuous disruption from AI, shifting student expectations, workforce pressures, and internal cultural resistance. The challenge leaders face is not how to implement change once, but how to build the institutional ability to adapt continuously. In this episode of the Changing Higher Ed® podcast, Dr. Drumm McNaughton speaks with Dr. Christine Janssen Founder and CEO of Edstutia, an immersive learning company focused on adult learning, about why higher education must move from traditional change models to an agile, iterative approach to leadership, teaching, and institutional strategy. Drawing on her experience in both higher education and entrepreneurial environments, Janssen explains why institutions struggle when they treat change as a project rather than an operating condition. McNaughton and Janssen outline how agile thinking, faculty adaptation, and a willingness to experiment have become essential leadership capabilities for presidents, boards, and faculty alike. Some of the Topics Covered: ·      Why traditional change management models no longer match today's environment ·      How agile, iterative approaches help institutions adapt faster than governance cycles ·      Why AI is exposing weaknesses in traditional teaching and assessment methods ·      The role of faculty culture as both a barrier and a solution to meaningful change ·      Why preparing students for uncertainty requires faculty to be comfortable with it ·      How institutions risk becoming the "yellow cab" in a world expecting "Uber-level" responsiveness Real-World Examples Discussed: ·      How AI forces faculty to redesign assignments and assessment methods ·      Why student evaluations often measure the wrong outcomes ·      How other industries were disrupted by ignoring customer expectations ·      Examples of leaders who prioritize faculty development and innovation Three Key Takeaways for Higher Education Leadership 1.     Institutions must change how they think about change before they can change behaviors. 2.     Faculty partnership and professional development are essential to institutional adaptability. 3.     The greatest risk to higher education is waiting to see what others will do. This episode offers higher education leaders a practical framework for understanding why many institutional struggles stem not from isolated issues, but from an outdated approach to change itself. Read the transcript:  https://changinghighered.com/agile-change-management-for-higher-education-leaders/   #HigherEducation #ChangeManagement #HigherEducationPodcast    

In the first episode of 2026, Recycled Content host Kara Pochiro hands hosting duties over to Maite Quinn-Richards, President of Resource Recycling. Maite is joined by APR Board members Michael Westerfield of Dart Container Corporation and Nicole Janssen of Denton Plastics for a preview of the key issues shaping the future of plastics recycling, which will be explored at the 2026 Plastics Recycling Conference (PRC) this February in San Diego. Drawing on perspectives from both brand manufacturing and recycling, the conversation explores current market pressures, recycled content demand, design for recyclability, and the growing role of EPR legislation. The episode also highlights PRC being held alongside the Resource Recycling Conference and the Textile Recovery Summit this year, and why policy, market development, and technical recycling conversations must happen together as the industry heads into 2026.   For more information about PRC visit plasticsrecycling.com.

(Insight Meditation Community of Richmond) There is a group of Theravāda monks right now, walking for peace from Texas to Washington DC. Their journey stands as a quiet yet powerful teaching, reminding us that even in times of unrest and difficulty, peace can begin with how we meet the moment.

(Insight Meditation Community of Richmond) There is a group of Theravāda monks right now, walking for peace from Texas to Washington DC. Their journey stands as a quiet yet powerful teaching, reminding us that even in times of unrest and difficulty, peace can begin with how we meet the moment.

This sermon was pre-recorded due to inclement weather on Sunday, Jan. 25. Stay warm! Support the showContact Village Presbyterian Churchvillagepres.orgcommunications@villagepres.org913-262-4200Have a prayer request? pastoral-care@villagepres.orgFacebook @villagepresInstagram @villagepreschurchYouTube @villagepresbyterianchurchTo join in the mission and ministry of Village Church, go to villagepres.org/giving

Aan tafel deze week: president van De Nederlandsche Bank Olaf Sleijpen, schrijvers Geert Mak en Roxane van Iperen en kunstenaar Julia Janssen.  Presentatie: Joost Vullings Wil je meer weten over de gasten in Buitenhof? Op onze website vind je meer informatie. Daar kan je deze aflevering ook terugkijken en je vindt er natuurlijk nog veel meer gesprekken: https://bit.ly/buitenhof-25jan26 De eerste maanden van zijn termijn als president van De Nederlandsche Bank staan bol van geopolitieke spanningen die ook sterke invloed kunnen hebben op de economie. Aan tafel de nieuwe president van De Nederlandsche Bank Olaf Sleijpen. Hoe moet Europa zich verhouden tot de grillen van Trump? En welk advies heeft hij voor de formerende partijen?  Na een week Davos is het overduidelijk: de wereldorde is veranderd. Hoe moet Europa zich opstellen in een autocratischere wereld waarin ook Amerika steeds verder afdrijft van democratische waarden? En kunnen we de binnenlandse Amerikaanse politiek los zien van het buitenlandbeleid? Daarover schrijvers Geert Mak en Roxane van Iperen. We vertrouwen steeds vaker op ChatGPT en vertellen de AI-chatbot onze diepste geheimen. Dat zal niet zonder gevolgen zijn volgens kunstenaar Julia Janssen. Met haar kunstproject Chadding, dat debuteerde in Davos, laat zij ChatGPT zelf verwoorden hoe het denkt de werkelijkheid te beïnvloeden.

As the Father sent the Son, so the Son sends us—breathed on and empowered by the Holy Spirit. Join us in worship as we encounter the living God and are commissioned together into His mission, a communal calling rooted in the love and life of the Trinity.

Negen feiten in amper één maand, waaronder drie moorden. Lange tijd leek Marc Eerdekens zich voor het hof van assisen te moeten verantwoorden voor een reeks gruwelijke moorden, moordpogingen en brandstichtingen in augustus 2020. Maar een hersenbloeding brengt daar mogelijk verandering in: volgens deskundigen is de Houthalense verdachte niet langer toerekeningsvatbaar. ­ Dit is een podcast aflevering van HBVL Crimi met host Tom Verstappen en journalist Geert Houben. ­ CREDITS: Journalist: Geert Houben. Host en redactie: Tom Verstappen. Opname en montage: Siebe Vanheusden en Geert Nies. Muziek: Pieter Santens (House of Media). Chef podcast: Geert Nies.­See omnystudio.com/listener for privacy information.

In the first episode of 2026, Recycled Content host Kara Pochiro hands hosting duties over to Maite Quinn-Richards, President of Resource Recycling. Maite is joined by APR Board members Michael Westerfield of Dart Container Corporation and Nicole Janssen of Denton Plastics for a preview of the key issues shaping the future of plastics recycling, which will be explored at the 2026 Plastics Recycling Conference (PRC) this February in San Diego. Drawing on perspectives from both brand manufacturing and recycling, the conversation explores current market pressures, recycled content demand, design for recyclability, and the growing role of EPR legislation. The episode also highlights PRC being held alongside the Resource Recycling Conference and the Textile Recovery Summit this year, and why policy, market development, and technical recycling conversations must happen together as the industry heads into 2026. For more information about PRC visit plasticsrecycling.com.

Saints du jour 2026-01-15 Saint Arnold Janssen et Saint Rémi by Radio Maria France

15 DE ENERO  - SAN ARNOLDO JANSSEN, PRESBÍTERO Y FUNDADOR

At the cross, God's love meets humanity's brokenness. Through Jesus' crucifixion, we are drawn back into relationship with the One who made us. Those who come are sent to bear witness to this restoring grace.

On episode 70 of the Innovators Podcast, Avery Smith, a Communications and Marketing Intern at the Iowa State University Research Park, interviews Ella Janssen, Founder of Monologue. In this episode, we dive into how Monologue came to be and the strides Ella has made in her short year in business. Thank you for listening!

In this episode, Rob Jones, Professor and Honorary Consultant in Medical Oncology at the University of Glasgow, UK,  joins us to discuss his journey into oncology, the future of the specialty, and the evolving treatment landscape for genitourinary cancers. From clinical trial design and emerging therapies to European Society for Medical Oncology (ESMO) 2025 takeaways and thoughts on prostate cancer screening, Jones shares practical insights drawn from both research and frontline clinical practice.  Timestamps:     00:00 – Introduction  00:43 – Rob's journey into oncology  04:11 – The next generation of oncologists  08:16 – Clinical trial work  10:20 – Intersection of oncology and nephrology  14:05 – Cardiovascular toxicity  19:25 – European Society for Medical Oncology (ESMO) 2025 bladder cancer takeaways  23:53 – Challenges in designing trials  26:35 – Emerging treatment strategies  30:18 – Prostate cancer screening  34:00 – Magic wishes for healthcare    Disclosure: Jones has received research grants from Astellas, Clovis, Exelixis, Bayer, and Roche; advisory board fees from Janssen, Astellas, Bayer, Novartis, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb; lecture honoraria from Astellas, Janssen, Bayer, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb; support for conference attendance from Bayer and Janssen; and participated on a Data Safety Monitoring Board or Advisory Board for Roche.

Long after the festivities fade, Christ remains the One we can rely on. Like the faithful ones who waited for Him with expectant hearts, we're invited to place our confidence in the Savior who never fails.

WGN-TV Meteorologist Mike Janssen joins Wendy Snyder (in for Bob Sirott) to talk about videos of recipes he makes for the Bears games every weekend, including this weekend’s Soul Rolls recipe. He also shares how he started creating his videos, how he got his start in making recipes, and the forecast for this weekend’s Bears […]

Dans cet extrait, l'humoriste raconte comment il a rencontré un suédois, chasseur de rennes... Pendant ces fêtes, retrouvez tous les jours en podcast une archive de l'émission spéciale Noël !Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dr. Christina Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman of International Science Nutrition Society and Chief Science Officer for ROOT Wellness. Dr. Rahm has also served as a formulator for several companies and manufacturing labs, including her own. She has created multiple provisional patents, proprietary formulas, and trade secrets in addition to authoring her first book, Cure the Causes: Live the Life you Want, Not the One Prescribed. Through years of laboratory research and ethical observations, she has developed a personalized and predictive consulting company working on everything from the environment to DNA and detox wellness plans in which Dr. Rahm helps clients reset their bodies and minds to be spiritually, mentally, emotionally, and physically balanced.

Welcome back to the studio.  This is My Day of Play, where you're taken into the real events and actions of how it happens long before the process of editing or cleaning up.  The original purpose of these episodes was to give my broadcasting students something to edit, to practice with and to call their own.  Then I realized that you are just as important.  Share the reality of how it really went.  We begin things with Victora Castillo creator of Fugitive Hunters Mexico on A&E. Then we'll leap into a revealing conversation with film and screenwriter Joshua Zetumer the creator of Hulu's/FX's Say Nothing. And we'll wrap things up with Sarah Janssen, the editor of one of the biggest selling books of all time… The Almanac!   This is My Day of Play.  Completely unedited in the way of meeting the wizard behind the curtain.  Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

Redemption is not just a future hope—it's a present reality in Christ.

Cam Janssen, born in St. Louis and raised in Eureka, Missouri is the first ever born-and-raised St. Louisan to suit up in the NHL. He was famous for the rough stuff in hockey, and takes great pride in it. He spent several seasons exciting the crowds at the Enterprise Center. Cam has a great way of telling a story…Enjoy!

At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to think a little differently about Giving Tuesday this year. We're sharing all the details about the Phase 2 clinical trial focusing on Moderna's investigational Epstein-Barr vaccine and MS (and we'll explain why that might turn out to be important!) We're talking about how MS impacts women's health issues with this year's winner of the Rachel Horne Prize for Women's Research in Multiple Sclerosis, Dr. Kristen Krysko. And we're sharing the results of the Phase 2 clinical trial for PIPE-307, an investigational remyelination therapy. We have a lot to talk about! Are you ready for RealTalk MS??! It's Giving Tuesday (and why that matters more this year than ever before)  :22 This Week: Becoming a caregiver for a parent with MS when you're 14 years old  3:27 A clinical trial focused on an EBV vaccine and MS is recruiting participants  4:25 Dr. Kristen Krysko discusses MS and women's health issues  7:52 Results from the Phase 2 clinical trial for PIPE-307 remyelination therapy  13:48 Michaela Janssen Pohl shares her story of becoming a caregiver at the age of 14  16:55 Share this episode  33:20 Next week's episode  33:40 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/431 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy PARTICIPATE: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://clinicaltrials.gov/study/NCT06735248 Email: WeCareClinicalTrials@modernatx.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 431 Guests: Dr. Kristen Krysko, Michaela Janssen Pohl Privacy Policy

God's Word helps us truly believe in Him that we may find true life in Him.

Elias Janssen is one of the stars of the new Netflix film IN YOUR DREAMS which is out today! The animated film is fun for the whole family and Gavin got to sit down with him to talk about the process and what it was like, as well as his personal life and career.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.